NCT06799039View on ClinicalTrials.gov

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients with Inflammatory Bowel Disease

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2030

Study Completion Date

September 1, 2031

Conditions

Inflammatory Bowel Disease (IBD)Clostridioides Difficile Infection

Interventions

DRUG

Xylitol

Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER